Chlortetracycline

證據等級: L5

預測適應症: 10 個

Chlortetracycline: From Broad-Spectrum Bacterial Infections to Postinfectious Vasculitis

One-Sentence Summary

Chlortetracycline (Aureomycin) is the world's first tetracycline antibiotic, historically developed for the treatment of broad-spectrum bacterial infections. The TxGNN model predicts it may have potential utility in Postinfectious Vasculitis — a condition characterised by persistent vascular inflammation following infection — with a prediction score of 99.82%. However, there are currently no clinical trials and no published literature directly supporting this specific indication, meaning this prediction rests entirely on model inference.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (historical use; no formal Singapore registration on record)
Predicted New Indication	Postinfectious Vasculitis
TxGNN Prediction Score	99.82%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Chlortetracycline belongs to the tetracycline class of antibiotics, which act by binding to the 30S ribosomal subunit of bacteria, thereby inhibiting protein synthesis. Beyond their antimicrobial properties, tetracyclines are well-documented to exert pleiotropic anti-inflammatory effects — most notably through inhibition of the NF-κB signalling pathway and downregulation of matrix metalloproteinases (MMPs). These secondary mechanisms are biologically relevant to vascular inflammation and tissue remodelling.

Postinfectious vasculitis is a condition in which the immune system continues to attack blood vessel walls after an acute infection has resolved. The pathophysiology involves dysregulated immune activation, persistent inflammatory cytokine release, and endothelial injury — all processes theoretically amenable to the immunomodulatory properties of tetracycline-class drugs. The TxGNN knowledge graph model likely captured this mechanistic overlap between tetracycline pharmacology and infection-driven vascular inflammatory pathways.

That said, the mechanistic link is analogical rather than direct. Chlortetracycline itself has lower oral bioavailability compared to later-generation tetracyclines such as doxycycline or minocycline, which are more frequently studied in inflammatory indications. No clinical or preclinical data specifically examining Chlortetracycline in postinfectious vasculitis currently exists. The prediction should be considered hypothesis-generating only, warranting evaluation of whether a more bioavailable tetracycline analogue would be a more suitable candidate for future study.

Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

Literature Evidence

Currently no related literature available for this indication.

Singapore Market Information

Chlortetracycline is currently not registered in Singapore. No product authorisations are on record.

Safety Considerations

Formal safety data — including package insert warnings, contraindications, and drug interaction profiles — was not retrievable for this assessment.

Please refer to the package insert and authoritative drug reference sources (e.g., DrugBank DB09093, WHO Essential Medicines documentation) for full safety information before any clinical consideration.

Key contextual safety points based on tetracycline class knowledge:

Photosensitivity: Tetracyclines are associated with photosensitive skin reactions.
Use in special populations: Contraindicated in pregnancy (risk of foetal bone and tooth development impairment) and in children under 8 years (dental staining and enamel hypoplasia).
Hepatotoxicity: High-dose or prolonged use may be associated with hepatic impairment.
Bioavailability interactions: Absorption is reduced by divalent cations (calcium, magnesium, iron, aluminium); avoid concurrent use with antacids, dairy products, and iron supplements.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high prediction score to Chlortetracycline for postinfectious vasculitis; however, this prediction is unsupported by any clinical trial, observational study, or published literature. Evidence level L5 — model prediction only — is insufficient to justify progression, and the mechanistic link is inferential rather than demonstrated. Additionally, Chlortetracycline is not registered in Singapore, and its pharmacokinetic profile (relatively poor oral bioavailability) makes it a suboptimal candidate compared to other tetracyclines within the same drug class.

To proceed, the following would be needed:

MOA clarification: Obtain verified pharmacological data from DrugBank (DB09093) to confirm whether Chlortetracycline's anti-inflammatory mechanisms are sufficiently distinct to justify study over doxycycline or minocycline.
Preclinical evidence search: Conduct a systematic literature review across EMBASE and MEDLINE using broader search terms (e.g., tetracycline + vasculitis, tetracycline + vascular inflammation) to determine if class-level evidence exists.
Class comparison: Evaluate whether doxycycline — a pharmacologically superior tetracycline with established anti-inflammatory data — would be a more appropriate repurposing candidate for this indication, rendering a Chlortetracycline-specific programme redundant.
Safety dossier: Retrieve the full TFDA package insert and complete DrugBank safety profile to enable a formal S1 safety review before any further investment.
Singapore regulatory pathway assessment: Determine whether a new drug application or a variation pathway would apply, given the current absence of Singapore market authorisation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.